Elevation Oncology, Inc. appointed Joseph J. Ferra, Jr. as Chief Executive Officer of the Company at the Company’s 2025 Annual Meeting of Stockholders, in each case, effective as of July 12, 2023 (the “Ferra Effective Date”). Mr. Ferra, age 48, served as the Company’s Chief Financial Officer since June 2021 and as the Company’s Interim Chief Executive Officer and President since January 2023. Mr. Ferra joined the Company from Syros Pharmaceuticals, Inc., where he served as Chief Financial Officer from March 2018 to June 2021.

Mr. Ferra received a B.S. in chemistry with distinction from Purdue University and an M.B.A. from The Stephen M. Ross School of Business at the University of Michigan. There are no arrangements or understandings between Mr. Ferra and any other persons, pursuant to which he was appointed as Chief Executive Officer and President, there are no family relationships among any of the Company’s directors or executive officers and Mr. Ferra, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.